Products for Research Use Only
RegisterLogin

3-Deazaneplanocin A

CAT: 0804-HY-10442-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10442-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
3-Deazaneplanocin A (DZNep) is a potent histone methyltransferase EZH2 inhibitor[1][2]. 3-Deazaneplanocin A is a potent S-adenosylhomocysteine hydrolase (AHCY) inhibitor. 3-Deazaneplanocin A shows anti-orthopoxvirus activity[6][7].
CAS Number
102052-95-9
Product Name Alternative
DZNep; 3-Deazaneplanocin
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Histone Methyltransferase; Orthopoxvirus; S-adenosylhomocysteine hydrolase (SAHH)
Type
Reference compound
Related Pathways
Anti-infection; Epigenetics; Metabolic Enzyme/Protease
Field of Research
Cancer; Infection; Inflammation/Immunology; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/3-deazaneplanocin-a.html
Purity
99.97
Solubility
H2O : 100 mg/mL (ultrasonic)
Smiles
O[C@@H]1[C@H](O)C(CO)=C[C@H]1N2C=NC3=C2C=CN=C3N
Molecular Formula
C12H14N4O3
Molecular Weight
262.26
Precautions
H302, H315, H319, H335
References & Citations
[1]Fiskus W, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood, 2009, 114 (13), 2733-2743.|[2]Avan A, et al. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther. 2012 Aug;11 (8) :1735-46.|[3]Kikuchi J, et al. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer. 2012 Nov;78 (2) :138-43.|[4]Sun F, et al. Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlus?. Eur J Pharm Sci. 2015 Sep 18;77:290-302.|[5]Siddiqi FS, et al. The Histone Methyltransferase Enzyme Enhancer of Zeste Homolog 2 Protects against Podocyte Oxidative Stress and Renal Injury in Diabetes. J Am Soc Nephrol. 2016 Jul;27 (7) :2021-34.|[6]Noriko Uchiyama, et al. Aristeromycin and DZNeP cause growth inhibition of prostate cancer via induction of mir-26a. Eur J Pharmacol. 2017 Oct 5;812:138-146.|[7]Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57 (1-2) :41-52.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
EZH2
Citation 01
BioRxiv. 2024 July 27.|Cancers (Basel) . 2022 Jul 23;14 (15) :3600.|Cell Death Dis. 2020 Oct 23;11 (10) :906.|Cell Death Dis. 2025 Apr 14;16 (1) :291.|Cell Death Discov. 2024 Jul 28;10 (1) :341.|Cell Rep. 2023 May 23;42 (6) :112550.|Cell Reprogram. 2017 Dec;19 (6) :363-371.|Cell Stem Cell. 2025 Aug 29;32 (10) :1509-1527.e9|Cells Tissues Organs. 2020;209 (4-6) :227-235.|Exp Eye Res. 2025 Sep 26:110670.|FASEB J. 2025 May 15;39 (9) :e70605.|Genes (Basel) . 2024 Sep 13;15 (9) :1206.|Int Immunopharmacol. 2022 May:106:108612.|J Am Soc Nephrol. 2016 Jul;27 (7) :2021-34. |J Exp Med. 2026 Jan 5;223 (1) :e20250603.|J Immunother Cancer. 2019 Nov 14;7 (1) :300. |J Mol Cell Cardiol. 2019 Oct:135:119-133.|Lab Invest. 2021 May;101 (5) :600-611.|Nat Commun. 2021 Feb 23;12 (1) :1237.|Patent. US20180263995A1.|Research Square Preprint. 2020 May.|Research Square Print. September 13th, 2022.|AMB Express. 2025 Jul 26;15 (1) :110.|Apoptosis. 2020 Oct;25 (9-10) :697-714.|Biochem Biophys Res Commun. 2018 Sep 10;503 (3) :2061-2067.|bioRxiv. 2023 Apr 21:2023.04.19.537556.|bioRxiv. 2024 May 18.|bioRxiv. 2025 Sep 14.|Cell Signal. 2024 Mar:115:111029.|Cell Stem Cell. 2025 Aug 7:S1934-5909 (25) 00262-0.|Exp Mol Pathol. 2020 Feb;112:104344.|J Clin Invest. 2025 July 22.|J Pharmacol Exp Ther. 2019 Sep;370 (3) :490-503.|Nat Commun. 2022 Jan 10;13 (1) :12.|Università degli Studi di CAGLIARI. Dipartimento di Scienze Biomediche. 2021 May.

Related Products

CatalogName
HY-W081226-013,3,3-Trifluoropropionyl chloride
HY-W127810-013,3',3''-Nitrilotripropionic Acid
HY-W4403031,1',3,3,3',3'-Hexamethylindotricarbocyanine (perchlorate)
HY-D1075-011,1',3,3,3',3'-Hexamethylindodicarbocyanine (iodide)
HY-W1146693- (3- (3-Ethoxy-3-oxopropoxy) propoxy) propanoicacid
HY-79034-013,3-Dimethylcyclohexanone
HY-131942SFTX-3.3
HY-178928KV1.3-IN-3
HY-176547FGFR2/3-IN-3
HY-15758-013,3'-Diindolylmethane

Alternative Products

CatalogName
007577-013-Deazaneplanocin A
A1905-253-Deazaneplanocin,DZNep
BD164895-013-Deazaneplanocin hydrochloride
T6360-013-deazaneplanocin A HCl
2444-2503-Deazaneplanocin A hydrochloride
27617-23-Deazaneplanocin (DZNep)
2409-1EZSolution™ 3-Deazaneplanocin A
A8182-5.13-Deazaneplanocin A (DZNep) hydrochloride
sc-3518563-Deazaneplanocin, HCl salt

Popular Products